ZA201907687B - Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same - Google Patents

Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same

Info

Publication number
ZA201907687B
ZA201907687B ZA2019/07687A ZA201907687A ZA201907687B ZA 201907687 B ZA201907687 B ZA 201907687B ZA 2019/07687 A ZA2019/07687 A ZA 2019/07687A ZA 201907687 A ZA201907687 A ZA 201907687A ZA 201907687 B ZA201907687 B ZA 201907687B
Authority
ZA
South Africa
Prior art keywords
salt
preparing
same
crystalline form
derivative compound
Prior art date
Application number
ZA2019/07687A
Other languages
English (en)
Inventor
Sang Ho Oh
Jong Gyun Kim
Se-Woong Oh
Tae Dong Han
Soo Yong Chung
Seong Ran Lee
Kyeong Bae Kim
Young Sung Lee
Woo Seob Shin
Hyun Ju
Jeong Ki Kang
Su Min Park
Dong Kyun Kim
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63857137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201907687(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of ZA201907687B publication Critical patent/ZA201907687B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
    • C07C303/22—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2019/07687A 2017-04-21 2019-11-20 Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same ZA201907687B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170051687 2017-04-21
PCT/KR2018/004473 WO2018194356A1 (en) 2017-04-21 2018-04-18 Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same

Publications (1)

Publication Number Publication Date
ZA201907687B true ZA201907687B (en) 2023-04-26

Family

ID=63857137

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/07687A ZA201907687B (en) 2017-04-21 2019-11-20 Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same

Country Status (23)

Country Link
US (3) US11453656B2 (enExample)
EP (1) EP3612529A4 (enExample)
JP (2) JP7126514B2 (enExample)
KR (3) KR102629654B1 (enExample)
CN (1) CN110869367B (enExample)
AR (1) AR111469A1 (enExample)
AU (2) AU2018256227B2 (enExample)
BR (1) BR112019021868A2 (enExample)
CA (1) CA3059543A1 (enExample)
CO (1) CO2019011578A2 (enExample)
EA (1) EA201992501A1 (enExample)
IL (2) IL270018B (enExample)
MA (1) MA49696A (enExample)
MX (2) MX392634B (enExample)
MY (1) MY201919A (enExample)
NZ (1) NZ758443A (enExample)
PH (1) PH12019502370A1 (enExample)
SA (1) SA519410342B1 (enExample)
SG (1) SG11201909615YA (enExample)
TW (1) TWI776882B (enExample)
UA (1) UA124364C2 (enExample)
WO (1) WO2018194356A1 (enExample)
ZA (1) ZA201907687B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
MY198379A (en) 2017-07-28 2023-08-28 Yuhan Corp Improved Process for Preparing Aminopyrimidine Derivatives
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
KR101973074B1 (ko) * 2018-11-30 2019-04-26 주식회사 티움바이오 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물
US12312329B2 (en) * 2018-12-21 2025-05-27 Shenzhen Targetrx, Inc. Aminopyrimidine compound used for inhibiting activity of protein kinase
US11459391B2 (en) 2019-02-26 2022-10-04 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
MX2021013955A (es) * 2019-05-14 2022-03-11 Janssen Biotech Inc Terapias de combinación con anticuerpos anti-egfr/c-met biespecíficos e inhibidores de tirosina quinasa de egfr de 3.a generación.
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
WO2022253261A1 (zh) 2021-06-01 2022-12-08 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech Inc Methods for treatment of non-small cell lung cancer (nsclc)
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1698623T3 (pl) 2003-12-25 2015-08-31 Eisai R&D Man Co Ltd Postać krystaliczna soli 4-(3-chloro-4-(cyklopropyloaminokarbonylo)aminofenoksy)-7-metoksy-6-chinolinokarboksamidu lub jej solwatu i sposoby ich wytwarzania
ES2565078T3 (es) 2004-02-11 2016-03-31 Natco Pharma Limited Forma polimorfa novedosa de mesilato de imatinib y un proceso para su preparación
EP2361248B1 (en) * 2008-06-27 2018-09-19 Celgene CAR LLC Heteroaryl compounds and uses thereof
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
WO2011060295A1 (en) 2009-11-13 2011-05-19 Genosco Kinase inhibitors
US9006448B2 (en) * 2010-12-06 2015-04-14 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and its salts
PT3009431T (pt) * 2011-07-27 2017-12-26 Astrazeneca Ab Compostos de 2-(2,4,5-anilino-substituídos)pirimidina como moduladores úteis do egfr para o tratamento do cancro
WO2015003571A1 (zh) 2013-07-08 2015-01-15 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的新晶型及其制备方法
JP6468611B2 (ja) 2014-05-13 2019-02-13 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
TWI730331B (zh) 2014-10-13 2021-06-11 南韓商柳韓洋行股份有限公司 用於調節ｅｇｆｒ突變型激酶活性的化合物及組成物
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
KR101794186B1 (ko) 2015-10-30 2017-11-08 한국기술교육대학교 산학협력단 전기자동차용 급전장치
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물

Also Published As

Publication number Publication date
CA3059543A1 (en) 2018-10-25
CO2019011578A2 (es) 2020-02-28
JP2022166179A (ja) 2022-11-01
US12428401B2 (en) 2025-09-30
UA124364C2 (uk) 2021-09-01
AU2022203486A1 (en) 2022-06-09
AR111469A1 (es) 2019-07-17
US11981659B2 (en) 2024-05-14
AU2018256227B2 (en) 2022-03-03
MY201919A (en) 2024-03-23
AU2022203486B2 (en) 2024-06-06
WO2018194356A1 (en) 2018-10-25
CN110869367B (zh) 2023-09-15
JP7390444B2 (ja) 2023-12-01
KR20230175161A (ko) 2023-12-29
AU2018256227A1 (en) 2019-10-31
KR102835717B1 (ko) 2025-07-18
EA201992501A1 (ru) 2020-02-18
IL294666B1 (en) 2024-01-01
TW201841910A (zh) 2018-12-01
IL294666B2 (en) 2024-05-01
IL270018B (en) 2022-08-01
TWI776882B (zh) 2022-09-11
EP3612529A4 (en) 2020-11-18
KR20180118535A (ko) 2018-10-31
MX2022006357A (es) 2022-06-23
KR20250111074A (ko) 2025-07-22
SG11201909615YA (en) 2019-11-28
NZ758443A (en) 2023-03-31
MA49696A (fr) 2020-06-03
US11453656B2 (en) 2022-09-27
KR102629654B1 (ko) 2024-01-29
IL294666A (en) 2022-09-01
EP3612529A1 (en) 2020-02-26
BR112019021868A2 (pt) 2020-05-26
JP7126514B2 (ja) 2022-08-26
IL270018A (enExample) 2019-12-31
SA519410342B1 (ar) 2023-02-09
US20210139461A1 (en) 2021-05-13
CN110869367A (zh) 2020-03-06
MX392634B (es) 2025-03-24
US20240279203A1 (en) 2024-08-22
US20230021395A1 (en) 2023-01-26
PH12019502370A1 (en) 2020-07-13
JP2020517611A (ja) 2020-06-18

Similar Documents

Publication Publication Date Title
ZA201907687B (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
IL273821A (en) A stereoselective process for the preparation of modified polycyclic pyridine derivatives
SI3497081T1 (sl) Postopek za pripravo 4-amonij-2,2,6,6-tetraalkilpiperidinilnih soli
IL267508B (en) A process for the preparation of 2-pyridylethyl carboxamide derivatives
IL265536A (en) A method for the production of a crystalline form of the a modification of calcobuterol
EP3275883A4 (en) Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
ZA201906848B (en) Novel pyrrolopyridine derivative, method for producing same, and use thereof
IL270789A (en) Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound
HK1255014A1 (zh) 制备取代5，6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法
IL275434B (en) A method for preparing a thiocarboxamidine salt compound
LT3592723T (lt) 3,3,3-trifluorprop-1-eno gavimo būdas
EP3353149A4 (en) PROCESS FOR THE PREPARATION OF INDOLIN COMPOUNDS AND A NOVEL INDOLIN SALT
IL271512B (en) A method for the preparation of modified 4-aminoindan derivatives
GB201600977D0 (en) Novel crystalline form of picoxystrobin, method of preparing use of the same
SI3190115T1 (sl) Sol derivata cefalosporina, njene trdne kristalinične oblike in postopek njene izdelave
IL290215A (en) A process for the preparation of crystalline form ii of sotagliflozin
IL273639A (en) A process for the preparation of pyrrolidine alpha-carboxamide derivatives
EP3681880A4 (en) PROCESS FOR THE PREPARATION OF CRYSTALLINE TIPIRACIL HYDROCHLORIDE
PL3717452T3 (pl) Sposób wytwarzania akilowanych pochodnych amfetaminy
GB2555344B (en) A process for preparing a novel crystalline form of iodosulfuron-methyl-sodium and use the same
IL268103A (en) A process for the preparation of chiral pyrrolidine-2-yl-methanol derivatives
HK40036649A (en) Process for preparing tapinarof
AU2017904453A0 (en) Process for preparing 2-substituted 3',4'-polyhydroxystilbene compounds
IL259332A (en) Process for the synthesis of intermediates useful for preparing 1,3,4-triazine derivatives
EP3591061A4 (en) MANUFACTURING PROCESS FOR USEFUL SUBSTANCES